Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children

Qingfeng Pharmaceutical

Status: Unknown

Conditions: Community Acquired Pneumonia

Study type: Observational

Funder types: Industry

Identifiers

NCT04158310

QF-XYP1908-2

Details and patient eligibility

About

In order to verify the clinical value and safety of Xiyanping injection in children with CAP, we intend to carry out this multi-center, large-sample, non-intervention clinical research through more rigorous and scientific design. Considering the current status of clinical research in children in China,research use real-world research methods.

Full description

This is an real world study of efficacy and safety of intravenous injection of Xiyanping injection in pediatric subjects with CAP.The purpose to determine the clinical value and influencing factors of Xiyanping injection in the treatment of community-acquired pneumonia in children based on real-world clinical data. The starting point for the study was the time at which the patient started treatment with Xiyanping injection or using a conventional treatment regimen; the end of follow-up was the date of the last visit to the patient, and if the patient had a disease progression or transfer, the date of the occurrence was the end. At the same time, baseline demographic characteristics (gender, date of birth, type of medical insurance, etc.), therapeutic drugs during the follow-up period, dose and time of use, laboratory indicators (such as white blood cells, C-reactive protein, etc., and examination time) were collected.

Enrollment: 9,207 estimated patients

Sex: All

Ages: 2 to 14 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 2 years old < age ≤ 14 years old children, male or female, diagnosed as community-acquired pneumonia diagnosed and need hospitalization

Exclusion criteria

• Acute infectious diseases such as measles, whooping cough, and influenza
• Other concomitant diseases or conditions that the investigators believe may interfere with the study, such as severe primary disease with severe heart, liver, kidney, digestive, and hematopoietic systems
• Children with severe malnutrition and previous history of immunodeficiency may seriously affect the self-limiting course of the disease
• Children with epilepsy and other central nervous system dysfunction
• Congenital diseases, mental patients
• Those who have used systemic hormones within 2 weeks before enrollment;
• Those who have used Qingrejiedu Chinese medicine within 2 weeks before enrollment
• The subject is poorly compliant (not according to the doctor's prescription or medical advice) or fails to timely feedback information

Trial design

9,207 participants in 2 patient groups

Standard treatment only

Description:

Standard treatment only such as antiasthmatic, expectorant and antipyretic

Standard treatment+Xiyanping injection

Description:

Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD.